VIM
ABBV icon

Vancity Investment Management’s AbbVie ABBV Stock Holding History

Vancity Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
1,204
+285
+31% +$63.2K 0.04% 78
2025
Q4 		$210K Buy
+919
New +$209K 0.03% 85

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vancity Investment Management's ABBV Position: Q1 2026 in Review

Vancity Investment Management increased its AbbVie (ABBV) stake by 31% in Q1 2026, buying an estimated $63.2K and bringing the position to 1,204 shares worth $262K. The position accounts for 0.04% of the portfolio, ranked #78.

Vancity Investment Management first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Vancity Investment Management held 1,204 shares of AbbVie worth $262K as of Q1 2026.
  • Vancity Investment Management bought 285 AbbVie shares in Q1 2026, an estimated $63.2K.
  • AbbVie made up 0.04% of Vancity Investment Management's portfolio in Q1 2026, its #78 holding.
  • Vancity Investment Management first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Vancity Investment Management's 13F filing for Q1 2026, filed 15 May 2026.